BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20963561)

  • 1. Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome.
    Macut D; Vojnović Milutinović D; Božić I; Matić G; Brkljačić J; Panidis D; Petakov M; Spanos N; Bjekić J; Stanojlović O; Petrović Milinković A; Radojičić Z; Damjanović S
    Endocrine; 2010 Feb; 37(1):129-34. PubMed ID: 20963561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome.
    Macut D; Božić Antić I; Nestorov J; Topalović V; Bjekić Macut J; Panidis D; Kastratović Kotlica B; Papadakis E; Matić G; Vojnović Milutinović D
    Hormones (Athens); 2015; 14(1):109-17. PubMed ID: 25402380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamic-pituitary-adrenocortical axis hypersensitivity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome.
    Milutinović DV; Macut D; Božić I; Nestorov J; Damjanović S; Matić G
    Exp Clin Endocrinol Diabetes; 2011 Nov; 119(10):636-43. PubMed ID: 22068557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid receptors on mononuclear leukocytes in polycystic ovary syndrome.
    Güven M; Açbay O; Sultuybek G
    Int J Gynaecol Obstet; 1998 Oct; 63(1):33-7. PubMed ID: 9849709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
    Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
    Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.
    Chen F; Chen M; Zhang W; Yin H; Chen G; Huang Q; Yang X; Chen L; Lin C; Yin G
    J Ovarian Res; 2021 Feb; 14(1):32. PubMed ID: 33583431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.
    Puurunen J; Piltonen T; Jaakkola P; Ruokonen A; Morin-Papunen L; Tapanainen JS
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1973-8. PubMed ID: 19318449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of adrenocortical steroidogenesis in women with post-adolescent severe acne and polycystic ovary syndrome.
    Cinar N; Cetinozman F; Aksoy DY; Elcin G; Yildiz BO
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):875-80. PubMed ID: 25176476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dehydroepiandrosterone sulfate/free androgen index ratio predicts a favorable metabolic profile in patients with polycystic ovary syndrome.
    Nadir A; Temizkan S; Ozderya A; Temizkan O; Orbay E; Aydin K
    Gynecol Endocrinol; 2019 Feb; 35(2):128-132. PubMed ID: 30324855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of Endocrinologic and Metabolic Parameters in Reproductive Age Polycystic Ovary Syndrome (PCOS) Women Concerning the Severity of Hyperandrogenemia-A New Insight on Syndrome Pathogenesis.
    Ozegowska K; Korman M; Szmyt A; Pawelczyk L
    Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33322590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?
    Meirow D; Raz I; Yossepowitch O; Brzezinski A; Rosler A; Schenker JG; Berry EM
    Hum Reprod; 1996 Sep; 11(9):1848-53. PubMed ID: 8921052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased ligand affinity rather than glucocorticoid receptor down-regulation in patients with endogenous Cushing's syndrome.
    Huizenga NA; De Herder WW; Koper JW; de Lange P; v D Lely AJ; Brinkmann AO; de Jong FH; Lamberts SW
    Eur J Endocrinol; 2000 May; 142(5):472-6. PubMed ID: 10802524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome.
    Faloia E; Canibus P; Gatti C; Frezza F; Santangelo M; Garrapa GG; Boscaro M
    J Endocrinol Invest; 2004 May; 27(5):424-9. PubMed ID: 15279073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome.
    Fassnacht M; Schlenz N; Schneider SB; Wudy SA; Allolio B; Arlt W
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2760-6. PubMed ID: 12788885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like factor 3 -- a new hormone related to polycystic ovary syndrome?
    Szydlarska D; Grzesiuk W; Trybuch A; Kondracka A; Kowalik I; Bar-Andziak E
    Endokrynol Pol; 2012; 63(5):356-61. PubMed ID: 23115068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome.
    Yildiz BO; Woods KS; Stanczyk F; Bartolucci A; Azziz R
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5558-62. PubMed ID: 15531511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 24-hour serum cortisol profiles in women with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Balint-Perić L
    Gynecol Endocrinol; 1993 Sep; 7(3):179-84. PubMed ID: 8291455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
    Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40.
    Liang SJ; Hsu CS; Tzeng CR; Chen CH; Hsu MI
    Hum Reprod; 2011 Dec; 26(12):3443-9. PubMed ID: 21926412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.